第 1 到 14 筆結果,共 14 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages | Ho, Hao; SUNG-LIANG YU ; Chen, Hsuan-Yu; Yuan, Shin-Sheng; KANG-YI SU ; Hsu, Yi-Chiung; Hsu, Chung-Ping; Chuang, Cheng-Yen; Chang, Ya-Hsuan; Li, Yu-Cheng; Cheng, Chiou-Ling; Chang, Gee-Chen; PAN-CHYR YANG ; Li, Ker-Chau | Lung cancer (Amsterdam, Netherlands) | 0 | 0 | |
2 | 2022 | Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma | Chi-ya Shen; Chang, Wen-Hsin; Chen, Yi-Ju; Weng, Chia-Wei; Regmi, Prabha; Kier, Mickiela K K; KANG-YI SU ; Chang, Gee-Chen; JIN-SHING CHEN ; Chen, Yu-Ju; SUNG-LIANG YU | Journal of proteome research | 4 | 0 | |
3 | 2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
4 | 2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
5 | 2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
6 | 2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
7 | 2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |
8 | 2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
9 | 2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |
10 | 2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
11 | 2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
12 | 2020 | Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression | Chen, Yi-Ju; Roumeliotis, Theodoros I; Chang, Ya-Hsuan; Chen, Ching-Tai; Han, Chia-Li; MIAO-HSIA LIN ; HUEI-WEN CHEN ; Chang, Gee-Chen; YIH-LEONG CHANG ; CHEN-TU WU ; MONG-WEI LIN ; MIN-SHU HSIEH ; Wang, Yu-Tai; Chen, Yet-Ran; Jonassen, Inge; Ghavidel, Fatemeh Zamanzad; Lin, Ze-Shiang; Lin, Kuen-Tyng; Chen, Ching-Wen; Sheu, Pei-Yuan; Hung, Chen-Ting; Huang, Ke-Chieh; Yang, Hao-Chin; Lin, Pei-Yi; Yen, Ta-Chi; Lin, Yi-Wei; Wang, Jen-Hung; Raghav, Lovely; Lin, Chien-Yu; Chen, Yan-Si; Wu, Pei-Shan; Lai, Chi-Ting; Weng, Shao-Hsing; KANG-YI SU ; Chang, Wei-Hung; Tsai, Pang-Yan; Robles, Ana I; Rodriguez, Henry; Hsiao, Yi-Jing; Chang, Wen-Hsin; Sung, Ting-Yi; JIN-SHING CHEN ; SUNG-LIANG YU ; Choudhary, Jyoti S; Chen, Hsuan-Yu; PAN-CHYR YANG ; Chen, Yu-Ju | Cell | 154 | 134 | |
13 | 2020 | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | Chang, Gee-Chen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen | Scientific reports | 26 | 20 | |
14 | 2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 47 | 45 |